Ontology highlight
ABSTRACT:
INSTRUMENT(S): Gene Titan
ORGANISM(S): Homo sapiens
SUBMITTER: Petra Ross-Macdonald
PROVIDER: E-MTAB-3218 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
Clinical cancer research : an official journal of the American Association for Cancer Research 20160511 22
<h4>Purpose</h4>Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell carcinoma (mRCC). We investigated immunomodulatory activity of nivolumab in a hypothesis-generating prospective mRCC trial.<h4>Experimental design</h4>Nivolumab was administered intravenously every 3 weeks at 0.3, 2, or 10 mg/kg to previously treated patients and 10 mg/kg to treatment-naïve patients with mRCC ...[more]